CME director awarded 1,067 shares in stock grants

SIEGEL HOWARD J reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

SIEGEL HOWARD J reported acquisition or exercise transactions in this Form 4 filing.

CME Group Inc. director Howard J. Siegel reported stock awards of Class A Common Stock as part of his non-employee director compensation. On June 25, 2026, he received 422 shares at $225 per share as a fully vested annual equity grant under the CME Group Director Stock Plan.

On the same date, he also received 645 fully vested shares at $225 per share, issued at his election in lieu of all or part of his annual cash retainer, with the share count based on the closing price on the grant date. Separately, the filing shows 21,873 shares of Class A Common Stock held indirectly by a trust.

Insider Trade Summary

Grant/Award: 1,067 shares

Grant/Award 3 txns

Insider SIEGEL HOWARD J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Class A	645	$225.00	$145K
Grant/Award	Common Stock Class A	422	$225.00	$95K
holding	Common Stock Class A	--	--	--

Holdings After Transaction: Common Stock Class A — 48,858 shares (Direct); Common Stock Class A — 21,873 shares (Indirect, by Trust)

Footnotes (2)

1. F1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.
2. F2. At the Reporting Person's election, shares issued in lieu of all or a portion of the annual cash retainer for serving as a member of the Board of Directors. The number of shares was determined by dividing the cash retainer by the closing price on the date of grant.

Key Figures

Annual director equity grant: 422 shares at $225 Shares in lieu of cash retainer: 645 shares at $225 Total shares awarded: 1,067 shares +2 more

5 metrics

Annual director equity grant 422 shares at $225 Fully vested Class A Common Stock grant on June 25, 2026

Shares in lieu of cash retainer 645 shares at $225 Fully vested shares issued instead of annual cash retainer

Total shares awarded 1,067 shares Sum of 422-share grant and 645-share retainer election

Trust-held indirect shares 21,873 shares Class A Common Stock held indirectly by trust

Grant price reference $225 per share Price used to determine director equity grants on grant date

Key Terms

fully vested shares, annual equity compensation program, CME Group Director Stock Plan, annual cash retainer, +1 more

5 terms

fully vested shares financial

"Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person"

annual equity compensation program financial

"issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors"

CME Group Director Stock Plan financial

"under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions."

annual cash retainer financial

"shares issued in lieu of all or a portion of the annual cash retainer for serving as a member of the Board of Directors."

closing price on the date of grant financial

"The number of shares was determined by dividing the cash retainer by the closing price on the date of grant."

FAQ

What did CME (CME) director Howard J. Siegel report in this Form 4?

Howard J. Siegel reported receiving stock awards of CME Group Class A Common Stock as director compensation. The filing shows fully vested shares granted under the director stock plan and additional shares taken instead of cash board retainer.

How many CME Group shares did Howard J. Siegel receive as equity compensation?

He received 422 fully vested shares of CME Class A Common Stock at $225 per share as part of CME Group’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan.

What additional CME shares did Howard J. Siegel elect instead of cash retainer?

He elected to receive 645 fully vested CME Class A shares in lieu of all or a portion of his annual cash retainer. The number of shares was calculated by dividing the cash retainer by the closing price on the grant date.

Are Howard J. Siegel’s new CME stock awards subject to vesting conditions?

The filing states the 422-share grant and the 645-share retainer-related issuance are fully vested. They were issued under CME Group’s director compensation arrangements and are not subject to any additional vesting conditions after the grant date.

How many CME shares does Howard J. Siegel hold indirectly via a trust?

The Form 4 shows 21,873 shares of CME Class A Common Stock held indirectly by a trust. This entry is reported as indirect ownership, separate from his directly held shares reported in the same filing.

Were Howard J. Siegel’s CME stock transactions open-market buys or routine grants?

They are routine grants and elections under CME’s director compensation programs, coded as “A” for grant or award. The footnotes describe fully vested stock grants and shares issued instead of cash retainer, not open-market purchases or sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SIEGEL HOWARD J

(Last) (First) (Middle)

20 S. WACKER DRIVE

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	06/25/2026		A(1)		645	A	$225	48,436	D
Common Stock Class A	06/25/2026		A(2)		422	A	$225	48,858	D
Common Stock Class A								21,873	I	by Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.

2. At the Reporting Person's election, shares issued in lieu of all or a portion of the annual cash retainer for serving as a member of the Board of Directors. The number of shares was determined by dividing the cash retainer by the closing price on the date of grant.

Remarks:

	/s/ Elizabeth Hensen, as Attorney-in-Fact for Howard J. Siegel	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)